Feasibility of CTDNA For Gynecologic Cancer in a Community / Teaching Hospitals
Document Type
Conference Proceeding
Publication Date
10-2026
Publication Title
Interanational Journal of Gynecological Cancer
Abstract
Introduction: To determine the relationship between ctDNA and CT findings in endometrial and ovarian cancer Methods: A chart review identified 46 patients with endometrial or ovarian cancer, ctDNA levels and recent imaging. Student’s t test was used to determine the significance between ctDNA and imaging findings in endometrial cancer and between ctDNA, CA125 and imaging findings in ovarian cancer. The sensitivity, specificity, PPV and NPV were calculated. Results: Of 46 patients, 13 had endometrial and 33 had ovarian cancer. In the 13 patients with endometrial cancer, 9 (69.2%) had findings on imaging; of these, 6 (66.67%) had elevated ctDNA levels. In patients without findings on CT scan, 0 (0%) had elevated ctDNA levels (p=0.024). Sensitivity of ctDNA was 75%, specificity was 100%, PPV 100%, NPV 57.14%. In the 33 patients with ovarian cancer, 21 (63.6%) had findings on imaging; of these, 15 (71.4%) had elevated ctDNA levels (p=0.0007) and 13 (62%) had elevated CA125 levels (p=0.009). Sensitivity of ctDNA was 77.78%, specificity was 92.31%, PPV 95.45% and NPV 66.67%. Sensitivity of CA125 was 72.41%, specificity was 85.71%, PPV 91.3% and NPV 60%. Conclusion/Implications: ctDNA was significantly associated with findings on imaging in endometrial and ovarian cancer with a stronger relationship for ovarian cancer. CA125 was also significantly associated with findings on imaging in ovarian cancer, but the relationship was stronger for ctDNA. ctDNA had high specificity and PPV, so it may be useful when there are indeterminate findings on imaging but should not be used as a sole marker given the lower NPV.
Volume
36
Issue
10 Suppl 1
First Page
20
Last Page
20
Recommended Citation
Stephens J, Hans A, Rosen B, Al-Wahab Z. Feasibility of CTDNA for gynecologic cancer in a community / teaching hospital. Int J Gynecol Cancer. 2026 Oct;36(10 Suppl 1):20. doi: 10.1016/j.ijgc.2026.105193
DOI
10.1016/j.ijgc.2026.105193
Comments
International Gynecological Cancer Society (IGCS) 2026 Annual Global Meeting, October 1-3, 2026, Montreal, Canada